Volv Global at Tech Tour Growth Health 2026
Tech Tour Growth Health is one of Europe’s most established gatherings at the intersection of healthcare innovation and investment – bringing together growth-stage digital health and medtech companies, leading investors, corporate partners, and ecosystem experts for two days of substantive exchange. This year’s edition takes place on 30 June – 1 July 2026 at IMD […]
Volv Global at the Life Sciences Innovation & Investment Corridor: Lausanne & London
Volv Global is pleased to be participating in the Life Sciences Innovation & Investment Corridor between Lausanne & London, hosted at ARC West London in Hammersmith on 29 April 2026. Organised by Innovaud in association with One Nucleus and ARC West London, the event brings together key life sciences stakeholders from the Swiss Health Valley […]
News article: When science fiction becomes science fact – AI for rare disease diagnosis
The idea that an AI system could detect a disease that appears nowhere in a patient’s medical record sounds like something from speculative fiction. At Volv Global, it is something we do today. In brief Volv Global is featured in The Biopôle Review, published by Biopôle Lausanne, as part of an exploration of how science […]
Volv Global at Faces of Industrial Research 2026
Introduction Volv Global participation in Faces of Industrial Research 2026 reflects its commitment to connecting scientific innovation with real-world healthcare impact. As conversations around translational science, industrial research, and health-tech careers continue to grow, this event offered an important opportunity to engage with students, researchers, and innovators interested in improving earlier disease recognition and patient […]
Volv Global at the Digital Lounge @Davos 2026
Photos from Digital Lounge @Davos. Volv Global CEO and founder Christopher Rudolf has been invited to speak at the Digital Lounge @Davos, on Thursday, January 22nd, 2026. The Digital Lounge @Davos is an invitation-only forum held alongside the Davos week in January 2026, bringing together senior leaders from healthcare, […]
Beyond the Hype: Volv Global CEO Christopher Rudolf at Frontiers Health 2025
Volv Global continues to shape the future of AI in healthcare. This November, at Frontiers Health 2025 in Berlin, CEO Christopher Rudolf will join global health leaders to discuss how credible, validated AI can transform patient access and healthcare delivery. The event celebrates a decade of digital health innovation, uniting stakeholders from pharma, biotech, med-tech, […]
Where Technology Meets Human: A Call to Unite Clinical Expertise and Real‑World Patient Voices
Léon van Wouwe, Clinical Innovation Director, Volv Global Since Volv Global first started attending the World Orphan Drug Congress, we have tried to listen to voices across the industry, and then acted in response to the needs we heard from every stakeholder. One concrete result: through our “Drive for Change” workshop and panel dialogues two […]
News Article: AI in healthcare
Introduction Artificial intelligence continues to push healthcare into a new era from early disease detection to large-scale data modelling. Yet expectations often move faster than real-world progress. This interview explores a grounded, data-centric perspective from Christopher Rudolf, Founder & CEO of Volv Global, who warns that while AI holds enormous potential, the healthcare sector must […]
World Orphan Drug Congress Europe 2025 | Volv Global in Amsterdam
Volv Global at WODC Europe 2025 – Where Technology Meets Human Volv Global sits at the crucial intersection between technology and human beings, i.e., patients and physicians, supporting favourable patient journeys and outcomes. We use each World Orphan Drug Congress as our touchpoint with the rare disease community, in particular as an opportunity to learn […]
Optimising Rare Disease Clinical Trials with Real World Data Using NLP & AI: Volv Global at the Rare Trials Summit 2025
Volv Global CEO and Founder Christopher Rudolf will speak on optimising rare disease clinical trials with Real World Data at the Rare Trials Summit 2025 in Boston in September. The development of inclusion/exclusion criteria for clinical trial protocols can make or break drug development. Can we expand medical knowledge and discover new phenotypes and […]